Dr. Eric D. Achtyes, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 41
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Michigan Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
MI license 4301081456
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bronson Methodist Hospital Kalamazoo, MI
Medical groups
- Western Michigan University School of Medicine (74 clinicians)
- Kalamazoo County Community Mental Health Authority (38 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 41
- Services billed
- 82
- Patients’ average age
- 59
| Service | Times | Patients |
|---|---|---|
| Injection of drug or substance under skin or into muscle | 17 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 25 payments worth $14,219 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,079 |
|---|---|
| Teva Pharmaceuticals USA, Inc. | $99.97 |
| Janssen Scientific Affairs, LLC | $39.09 |
| Consulting Fee | $11,413 |
|---|---|
| Travel and Lodging | $2,076 |
| Food and Beverage | $730 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Consulting Fee | $5,785 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 14, 2025 | Consulting Fee | $2,958 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 8, 2025 | Consulting Fee | $2,670 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 24, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $570 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 9, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $545 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 10, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $208 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 30, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $203 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 30, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 15, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $134 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 8, 2025 | Consulting Fee | $2,670 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 30, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jun 30, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $203 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Consulting Fee | $5,785 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 10, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $208 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 9, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $545 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 15, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $134 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 15, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $134 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 24, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $570 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 14, 2025 | Consulting Fee | $2,958 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $98,582 in research payments for these studies, mostly to the institutions running them.
- A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia
Boehringer Ingelheim International GmbH - TV50717-CNS-40223
Teva Pharmaceuticals USA, Inc. - A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
E.r. Squibb & Sons, L.l.c. - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.